Following a full submission.
Omalizumab (Xolair®) is not recommended for use within NHS Scotland as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma.
The economic case for omalizumab has not been demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice111KB (PDF)
- Medicine name:
- Omalizumab 150mg powder and solvent for injection (Xolair)
- SMC ID:
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 12 June 2006